Evidence map›Paper›PMID 39334990›Full record

ReviewAntibiotics (Basel, Switzerland)2024

Origami of KR-12 Designed Antimicrobial Peptides and Their Potential Applications.

Jayaram Lakshmaiah Narayana, Abraham Fikru Mechesso, Imran Ibni Gani Rather, D Zarena, Jinghui Luo, Jingwei Xie, Guangshun Wang

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Whole-Genome Sequencing of Multidrug-ResistantInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Veterinary research forum : an international quarterly journal · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jayaram Lakshmaiah NarayanaDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.
Abraham Fikru MechessoDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.
Imran Ibni Gani RatherDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.
D ZarenaDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-8826-4558
Jinghui LuoDepartment of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Jingwei XieDepartment of Surgery-Transplant and Mary & Dick Holland Regenerative Medicine Program, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Guangshun WangDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-4841-7927

Funding

Novel Janus-type Antimicrobial Dressings for the Treatment of Biofilms in Chronic WoundsR01GM138552 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, GUANGSHUN, XIE, JINGWEI · 2020 to 2023
$2.2M
Novel antimicrobials to combat Gram-negative bacteriaR56AI175209 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MURRY, DARYL, WANG, GUANGSHUN · 2023 to 2023
$384k
NIAID NIH HHS R56 AI175209NIGMS NIH HHS R01 GM138552NIH HHS AI175209NIH HHS GM138552
6 · The paper itself

Abstract

This review describes the discovery, structure, activity, engineered constructs, and applications of KR-12, the smallest antibacterial peptide of human cathelicidin LL-37, the production of which can be induced under sunlight or by vitamin D. It is a moonlighting peptide that shows both antimicrobial and immune-regulatory effects. Compared to LL-37, KR-12 is extremely appealing due to its small size, lack of toxicity, and narrow-spectrum antimicrobial activity. Consequently, various KR-12 peptides have been engineered to tune peptide activity and stability via amino acid substitution, end capping, hybridization, conjugation, sidechain stapling, and backbone macrocyclization. We also mention recently discovered peptides KR-8 and RIK-10 that are shorter than KR-12. Nano-formulation provides an avenue to targeted delivery, controlled release, and increased bioavailability. In addition, KR-12 has been covalently immobilized on biomaterials/medical implants to prevent biofilm formation. These constructs with enhanced potency and stability are demonstrated to eradicate drug-resistant pathogens, disrupt preformed biofilms, neutralize endotoxins, and regulate host immune responses. Also highlighted are the safety and efficacy of these peptides in various topical and systemic animal models. Finaly, we summarize the achievements and discuss future developments of KR-12 peptides as cosmetic preservatives, novel antibiotics, anti-inflammatory peptides, and microbiota-restoring agents.

Indexed as

antimicrobial peptidesKR-12lipopeptidesLL-37macrocyclic peptidesstapled peptidesTrp-caged peptides

Identifiers

PMID39334990
PMCPMC11429261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.